TNFRSF17 and plasma cell myeloma: However, the heterogeneity of BCMA expression on multiple myeloma cells allows anti-BCMA CAR-T cells to preferentially target multiple myeloma cells with high BCMA expression, while to retain multiple myeloma cells with low or no BCMA expression for clonal growth (19–21).